Literature DB >> 28228261

Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.

Michelle Cicchini1, Elizabeth L Buza2, Kyra M Sagal1, A Andrea Gudiel1, Amy C Durham2, David M Feldser3.   

Abstract

Expression of oncogenic KrasG12D initiates lung adenomas in a mitogen-activated protein kinase (MAPK) signal-dependent manner from only a subset of cell types in the adult mouse lung. Amplification of MAPK signaling is associated with progression to malignant adenocarcinomas, but whether this is a cause or a consequence of disease progression is not known. To better understand the effects of MAPK signaling downstream of KrasG12D expression, we capitalized on the ability of Braf inhibition to selectively amplify MAPK pathway signaling in KrasG12D-expressing epithelial cells. MAPK signal amplification indeed promoted the rapid progression of established adenomas to malignant adenocarcinomas. However, we observed, surprisingly, a greater number of overall tumor-initiating events after MAPK signal amplification, due to induced proliferation of cell types that are normally refractory to KrasG12D-induced transformation. Thus, MAPK signaling in the lung is thresholded not only during malignant progression but also at the moment of tumor initiation.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kras; MAPK; lung adenocarcinoma; p53

Mesh:

Substances:

Year:  2017        PMID: 28228261      PMCID: PMC5405440          DOI: 10.1016/j.celrep.2017.01.069

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  50 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Authors:  Anny Shai; David Dankort; Joseph Juan; Shon Green; Martin McMahon
Journal:  Cancer Res       Date:  2015-05-22       Impact factor: 12.701

3.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

4.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

5.  Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.

Authors:  Seyed Javad Moghaddam; Huaiguang Li; Sung-Nam Cho; Megan K Dishop; Ignacio I Wistuba; Lin Ji; Jonathan M Kurie; Burton F Dickey; Francesco J Demayo
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-16       Impact factor: 6.914

6.  Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination.

Authors:  Michal Safran; William Y Kim; Andrew L Kung; James W Horner; Ron A DePinho; William G Kaelin
Journal:  Mol Imaging       Date:  2003-10       Impact factor: 4.488

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

9.  Stage-specific sensitivity to p53 restoration during lung cancer progression.

Authors:  David M Feldser; Kamena K Kostova; Monte M Winslow; Sarah E Taylor; Chris Cashman; Charles A Whittaker; Francisco J Sanchez-Rivera; Rebecca Resnick; Roderick Bronson; Michael T Hemann; Tyler Jacks
Journal:  Nature       Date:  2010-11-25       Impact factor: 49.962

10.  Recombinase-based conditional and reversible gene regulation via XTR alleles.

Authors:  Camila Robles-Oteiza; Sarah Taylor; Travis Yates; Michelle Cicchini; Brian Lauderback; Christopher R Cashman; Aurora A Burds; Monte M Winslow; Tyler Jacks; David M Feldser
Journal:  Nat Commun       Date:  2015-11-05       Impact factor: 14.919

View more
  14 in total

1.  Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function.

Authors:  Xiaorong Zhou; Mahesh S Padanad; Bret M Evers; Bethany Smith; Nicole Novaresi; Shruthy Suresh; James A Richardson; Emily Stein; Jingfei Zhu; Robert E Hammer; Kathryn A O'Donnell
Journal:  Mol Cancer Res       Date:  2018-11-08       Impact factor: 5.852

2.  The role of MAPK signaling pathway in formation of EMT in oral squamous carcinoma cells induced by TNF-α.

Authors:  Xiao-Wei Zhao; Jing-Ping Zhou; Yu-Lan Bi; Jia-Ying Wang; Rui Yu; Chao Deng; Wei-Kang Wang; Xian-Zhen Li; Rui Huang; Jili Zhang; De-Tao Tao
Journal:  Mol Biol Rep       Date:  2019-04-15       Impact factor: 2.316

3.  Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.

Authors:  Özgün Le Roux; Nicole L K Pershing; Erin Kaltenbrun; Nicole J Newman; Jeffrey I Everitt; Elisa Baldelli; Mariaelena Pierobon; Emanuel F Petricoin; Christopher M Counter
Journal:  Elife       Date:  2022-09-07       Impact factor: 8.713

4.  The ERBB network facilitates KRAS-driven lung tumorigenesis.

Authors:  Björn Kruspig; Tiziana Monteverde; Sarah Neidler; Andreas Hock; Emma Kerr; Colin Nixon; William Clark; Ann Hedley; Sarah Laing; Seth B Coffelt; John Le Quesne; Craig Dick; Karen H Vousden; Carla P Martins; Daniel J Murphy
Journal:  Sci Transl Med       Date:  2018-06-20       Impact factor: 17.956

5.  AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.

Authors:  Jean Ching-Yi Tien; Seema Chugh; Andrew E Goodrum; Yunhui Cheng; Rahul Mannan; Yuping Zhang; Lisha Wang; Vijaya L Dommeti; Xiaoming Wang; Alice Xu; Jennifer Hon; Carson Kenum; Fengyun Su; Rui Wang; Xuhong Cao; Sunita Shankar; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

6.  ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

Authors:  Mohamed I Saad; Sultan Alhayyani; Louise McLeod; Liang Yu; Mohammad Alanazi; Virginie Deswaerte; Ke Tang; Thierry Jarde; Julian A Smith; Zdenka Prodanovic; Michelle D Tate; Jesse J Balic; D Neil Watkins; Jason E Cain; Steven Bozinovski; Elizabeth Algar; Tomohiro Kohmoto; Hiromichi Ebi; Walter Ferlin; Christoph Garbers; Saleela Ruwanpura; Irit Sagi; Stefan Rose-John; Brendan J Jenkins
Journal:  EMBO Mol Med       Date:  2019-04       Impact factor: 12.137

7.  Adaptively Weighted and Robust Mathematical Programming for the Discovery of Driver Gene Sets in Cancers.

Authors:  Xiaolu Xu; Pan Qin; Hong Gu; Jia Wang; Yang Wang
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

8.  Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase.

Authors:  J Edward van Veen; Michael Scherzer; Julia Boshuizen; Mollee Chu; Annie Liu; Allison Landman; Shon Green; Christy Trejo; Martin McMahon
Journal:  Elife       Date:  2019-08-27       Impact factor: 8.140

9.  NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity.

Authors:  Kelley Ingram; Shiela C Samson; Rediet Zewdu; Rebecca G Zitnay; Eric L Snyder; Michelle C Mendoza
Journal:  Oncogene       Date:  2021-10-23       Impact factor: 9.867

10.  Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Nathiya Muthalagu; Tiziana Monteverde; Ximena Raffo-Iraolagoitia; Robert Wiesheu; Declan Whyte; Ann Hedley; Sarah Laing; Björn Kruspig; Rosanna Upstill-Goddard; Robin Shaw; Sarah Neidler; Curtis Rink; Saadia A Karim; Katarina Gyuraszova; Colin Nixon; William Clark; Andrew V Biankin; Leo M Carlin; Seth B Coffelt; Owen J Sansom; Jennifer P Morton; Daniel J Murphy
Journal:  Cancer Discov       Date:  2020-03-21       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.